SCHEMBL23778231

SCHEMBL23778231

CCC1CN(C2CCC(C#N)(c3ccncc3)CC2)CCCN1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.44
PRKCB P05771 5/20 0.36
KDM1A O60341 1/20 0.36
PREP P48147 1/20 0.35
LCK P06239 2/20 0.33
JAK3 P52333 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
PDE4A P27815 2/20 0.33
PDE4B Q07343 2/20 0.33
PDE4C Q08493 2/20 0.33
PDE4D Q08499 2/20 0.33
DPP4 P27487 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
CCR2 P41597 1/20 0.32
KDM2B Q8NHM5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23778274 0.91 CYP2D6 (0.52) CYP2D6PRKCBKDM1AMEN1KMT2A
SCHEMBL23778336 0.89 CYP2D6 (0.57) CYP2D6PRKCBKDM1APDE4APDE4B
SCHEMBL23778310 0.89 CYP2D6 (0.46) CYP2D6PRKCBKDM1AKMT2APDE4A
SCHEMBL23778283 0.87 CYP2D6 (0.44) CYP2D6PDE4APDE4BPDE4CPDE4D
SCHEMBL23778233 0.84 CYP2D6 (0.44) CYP2D6PRKCBKDM1AMEN1KMT2A
SCHEMBL23778346 0.84 PRKCB (0.43) CYP2D6PRKCBKDM1ADPP4CCR2
SCHEMBL23778264 0.84 CYP2D6 (0.39) CYP2D6PRKCBKDM1APREPKMT2A
SCHEMBL23778279 0.83 CYP2D6 (0.49) CYP2D6PRKCBKDM1APDE4APDE4B
SCHEMBL23778249 0.83 CYP2D6 (0.43) CYP2D6PRKCBKDM1AMEN1KMT2A
SCHEMBL23778427 0.83 CYP2D6 (0.48) CYP2D6KDM1AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526207-B1 HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. HEPTARES THERAPEUTICS LTD (GB) 2021-09-08 EP claimed